Table 1.
Summary of reported PPFE cases after bone marrow transplantation.
| Source | Patients | Age | Sex | Underlying disease | Manifestation after BMT (years) | Histological findings |
|---|---|---|---|---|---|---|
| Present case | 1 | 30 | M | ALL | 16 | PPFE, BO, cellular and fibrotic NSIP |
| Thusen, 2011 [5] | 4 | 13 | F | AA | 2.8 | subpleural fibrosis, BO, mild patchy inflammation |
| 23 | M | AML | 12 | subpleural and paraseptal fibroelastosis, BO | ||
| 32 | M | ALL | 16 | subpleural fibroelastosis, BO, pneumothorax | ||
| 55 | F | AML | 2 | PPFE, BO, widespread pulmonary fibrosis | ||
| Fujikura, 2014 [7] | 1 | 31 | F | ALL | 9 | PPFE, BO |
| Takeuchi, 2015 [6] | 20 | 27.5 (8–57) | 11 M 9 F |
AML (12) MDS (2) ALL (1) Primary macroglobulinemia (1) SCID (1) Aplastic anemia (1) Chediak-Higashi syndrome (1) Neuroblastoma (1) |
1.2 (0.4–3.8) | BO (20) PPFE (15) NSIP fibrotic (9) NSIP cellular (6) |
| Mariani, 2016 [4] | 2 | 33 | M | AML | 13 | PPFE was diagnosed by HRCT |
| 61 | F | AML | 5 | |||
| Matsui, 2016 [11] | 1 | 40 | M | HL | 2.7 | PPFE, diffuse interstitial fibrosis |
| Ishii, 2016 [8] | 5 | 44 | F | MDS (RA) | 3.3 | PPFE, fibrotic lesions, no significant inflammatory cell infiltration |
| 27 | M | MDS (RA) | 1.1 | |||
| 38 | M | CML | 9.1 | |||
| 28 | M | ALL | 6.4 | |||
| 50 | M | AA | 8.8 | |||
| Cha, 2017 [9] | 2 | 54 | M | AML | 2 | PPFE, diffuse lymphocytic infiltration |
| 16 | M | AML | n/a | PPFE, BO, patchy lymphocytic infiltration | ||
| Okimoto, 2018 [10] | 1 | 45 | F | MDS | 5 | PPFE |
AA, aplastic anemia.
ALL, acute lymphoblastic leukemia.
AML, acute myeloid leukemia.
BO, bronchiolitis obliterans
BMT, bone marrow transplantation.
CML, chronic myeloid leukemia.
HL, Hodgkin lymphoma.
HRCT, high resolution computed tomography.
MDS, myelodysplastic syndrome.
NSIP, non-specific interstitial pneumonia.
RA, refractory anemia.
SCID, severe combined immunodeficiency.